Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas

Cancer

Volumn 112, Issue 11, 2008, Pages 2432-2439

  Ryan, Christopher W ^a   Montag, Anthony G ^b   Hosenpud, Janet R ^c   Samuels, Brian ^d   Hayden, James B ^e   Hung, Arthur Y ^a   Mansoor, Atiya ^a   Peabody, Terrance D ^b   Mundt, Arno J ^f   Undevia, Samir ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d North Idaho Cancer Center   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemoradiation; Chemotherapy; Clinical trial; Sarcoma

Indexed keywords

COLONY STIMULATING FACTOR; EPIRUBICIN; IFOSFAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONFUSION; CONSCIOUSNESS; CONSTIPATION; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY FAILURE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PAIN; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION NECROSIS; SIDE EFFECT; SOFT TISSUE SARCOMA; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TUMOR VOLUME; VOMITING; CANCER STAGING; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; PREOPERATIVE CARE; RISK FACTOR; SARCOMA; SOFT TISSUE TUMOR; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; EPIRUBICIN; FEMALE; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; NEOPLASM STAGING; PREOPERATIVE CARE; RISK FACTORS; SARCOMA; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME;

EID: 52049083450     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23478     Document Type: Article

References (30)

1. Suit HD, Russell WO, Martin RG. Sarcoma of soft tissue: clinical and histopathologic parameters and response to treatment. Cancer. 1975;35:1478-1483.
2. Lindberg RD, Martin RG, Romsdahl MM, Barkley HT Jr. Conservative surgery and postoperative radiotherapy in 300 adults with soft-tissue sarcomas. Cancer. 1981;47:2391-2397.
3. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16:197-203.
4. Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol. 2003;21:2719-2725.
5. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997;350:1647-1654.
6. Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19:1238-1247.
7. Cormier JN, Huang X, Xing Y, et al. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at 2 cancer centers: chemotherapy-associated outcomes. J Clin Oncol. 2004;22:4567-4574.
8. O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359:2235-2241.
9. Gortzak E, Azzarelli A, Buesa J, et al. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer. 2001;37:1096-1103.
10. Kraybill WG, Harris J, Spiro IJ, et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol. 2006;24:619-625.
11. DeLaney TF, Spiro IJ, Suit HD, et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys. 2003;56:1117-1127.
12. Mack LA, Crowe PJ, Yang JL, et al. Preoperative chemoradiotherapy (modified Eilber protocol) provides maximum local control and minimal morbidity in patients with soft tissue sarcoma. Ann Surg Oncol. 2005;12:646-653.
13. Eilber F, Eckardt J, Rosen G, Forscher C, Selch M, Fu YS. Preoperative therapy for soft tissue sarcoma. Hematol Oncol Clin North Am. 1995;9:817-823.
14. Davis AM, O'Sullivan B, Turcotte R, et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol. 2005;75:48-53.
15. Eilber FC, Rosen G, Eckardt J, et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol. 2001;19:3203-3209.
16. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
17. Simon R. Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
18. Goldman AI. Issues in designing sequential stopping rules for monitoring side effects in clinical trials. Control Clin Trials. 1987;8:327-337.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
21. Pisters PW, Patel SR, Prieto VG, et al. Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. J Clin Oncol. 2004;22:3375-3380.
22. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776-790.
23. Picci P, Bohling T, Bacci G, et al. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J Clin Oncol. 1997;15:1553-1559.
24. Pisters PW, Patel SR, Varma DG, et al. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J Clin Oncol. 1997;15:3481-3487.
25. Pezzi CM, Pollock RE, Evans HL, et al. Preoperative chemotherapy for soft-tissue sarcomas of the extremities. Ann Surg. 1990;211:476-481.
26. Meric F, Hess KR, Varma DG, et al. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer. 2002;95:1120-1126.
27. Schuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer. 2005;103:339-348.
28. Schuetze SM, Eary JF, Griffith KA, et al. FDG PET but not RECIST agrees with histologic response of soft tissue sarcoma to neoadjuvant chemotherapy. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol. 2005;23(16S, pt I of II [June 1 suppl]):9005.
29. Worden FP, Taylor JM, Biermann JS, et al. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J Clin Oncol. 2005;23:105-112.
30. Patel SR, Vadhan-Raj S, Papadopolous N, et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies-dose-response and schedule dependence. J Clin Oncol. 1997;15:2378-2384.